• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired.

作者信息

Crossman David, Rothman Alexander

机构信息

School of Medicine, University of St Andrews, North Haugh, St Andrews, Scotland.

The Medical School, University of Sheffield, Sheffield, England.

出版信息

J Thorac Dis. 2017 Dec;9(12):4922-4925. doi: 10.21037/jtd.2017.11.96.

DOI:10.21037/jtd.2017.11.96
PMID:29312693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5756992/
Abstract
摘要

相似文献

1
The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired.卡那单抗抗炎血栓形成结果研究试验——起跑枪已经打响。
J Thorac Dis. 2017 Dec;9(12):4922-4925. doi: 10.21037/jtd.2017.11.96.
2
Canakinumab and cardiovascular outcomes: results of the CANTOS trial.卡那单抗与心血管结局：CANTOS试验结果
J Community Hosp Intern Med Perspect. 2018 Feb 6;8(1):21-22. doi: 10.1080/20009666.2018.1428023. eCollection 2018.
3
Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.在用卡那单抗成功抑制白细胞介素-1β后，白细胞介素-18和白细胞介素-6相关的残余炎症风险：开发靶向抗细胞因子疗法治疗动脉粥样硬化血栓形成的进一步理论依据。
Eur Heart J. 2020 Jun 14;41(23):2153-2163. doi: 10.1093/eurheartj/ehz542.
4
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
5
The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.卡那奴单抗用于心血管疾病二级预防的成本效益：澳大利亚医疗保健视角。
Int J Cardiol. 2019 Jun 15;285:1-5. doi: 10.1016/j.ijcard.2019.01.037. Epub 2019 Jan 15.
6
The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.抑制炎症在治疗动脉粥样硬化性心血管疾病中的作用。
Ann Pharmacother. 2020 Oct;54(10):1021-1029. doi: 10.1177/1060028020922994. Epub 2020 May 19.
7
A case report of locally invasive infection in a patient on canakinumab.1例使用卡那单抗的患者发生局部侵袭性感染的病例报告
Eur Heart J Case Rep. 2018 Sep 4;2(3):yty098. doi: 10.1093/ehjcr/yty098. eCollection 2018 Sep.
8
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.可切除非小细胞肺癌患者接受卡那单抗联合和不联合帕博利珠单抗治疗的研究：CANOPY-N 研究设计。
Future Oncol. 2021 Apr;17(12):1459-1472. doi: 10.2217/fon-2020-1098. Epub 2021 Mar 2.
9
Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).卡那单抗抑制白细胞介素-1β与降低肺癌——卡那单抗抗炎血栓形成结局研究试验（CANTOS）的亚组分析
J Thorac Dis. 2018 Sep;10(Suppl 26):S3084-S3087. doi: 10.21037/jtd.2018.07.50.
10
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.卡那单抗抑制白细胞介素-1β对动脉粥样硬化患者肺癌发病的影响：一项随机、双盲、安慰剂对照试验的探索性结果。
Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27.

引用本文的文献

1
Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential.心力衰竭的分子机制及其治疗潜力。
Cells. 2025 Feb 20;14(5):324. doi: 10.3390/cells14050324.
2
Features of the monocyte inflammatory response in patients with premature coronary artery disease.早发性冠状动脉疾病患者单核细胞炎症反应的特征
Biophys Rep. 2025 Feb 28;11(1):12-17. doi: 10.52601/bpr.2024.240030.
3
Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes.急性冠脉综合征中炎症与新发心房颤动之间的关联
J Clin Med. 2024 Aug 27;13(17):5088. doi: 10.3390/jcm13175088.
4
Beyond the Basics: Unraveling the Complexity of Coronary Artery Calcification.超越基础：揭开冠状动脉钙化的复杂性。
Cells. 2023 Dec 12;12(24):2822. doi: 10.3390/cells12242822.
5
Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).卡那单抗抑制白细胞介素-1β与降低肺癌——卡那单抗抗炎血栓形成结局研究试验（CANTOS）的亚组分析
J Thorac Dis. 2018 Sep;10(Suppl 26):S3084-S3087. doi: 10.21037/jtd.2018.07.50.

本文引用的文献

1
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.卡那单抗治疗后 C 反应蛋白降低与心血管事件减少的关系：来自 CANTOS 随机对照试验的二次分析。
Lancet. 2018 Jan 27;391(10118):319-328. doi: 10.1016/S0140-6736(17)32814-3. Epub 2017 Nov 13.
2
Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.白细胞介素-1β作为动脉粥样硬化治疗靶点：CANTOS研究及其他的生物学基础
J Am Coll Cardiol. 2017 Oct 31;70(18):2278-2289. doi: 10.1016/j.jacc.2017.09.028.
3
Monocyte-Macrophages and T Cells in Atherosclerosis.动脉粥样硬化中的单核细胞-巨噬细胞与T细胞
Immunity. 2017 Oct 17;47(4):621-634. doi: 10.1016/j.immuni.2017.09.008.
4
Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.英国TRANSFORM研究的临床试验方案：一项关于托珠单抗治疗肺动脉高压的开放性治疗研究。
Pulm Circ. 2018 Jan-Mar;8(1):2045893217735820. doi: 10.1177/2045893217735820. Epub 2017 Sep 28.
5
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.卡那单抗抑制白细胞介素-1β对动脉粥样硬化患者肺癌发病的影响：一项随机、双盲、安慰剂对照试验的探索性结果。
Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27.
6
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
7
Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling.由BMPR2缺乏诱导的差异性白细胞介素-1信号传导驱动肺血管重塑。
Pulm Circ. 2017 Oct-Dec;7(4):768-776. doi: 10.1177/2045893217729096. Epub 2017 Sep 22.
8
Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.血管炎症与低密度脂蛋白：胆固醇是其中的联系吗？临床试验的启示。
Br J Pharmacol. 2017 Nov;174(22):3973-3985. doi: 10.1111/bph.13805. Epub 2017 May 5.
9
Anti cytokine therapy in chronic inflammatory arthritis.慢性炎症性关节炎的抗细胞因子治疗
Cytokine. 2016 Oct;86:92-99. doi: 10.1016/j.cyto.2016.07.015. Epub 2016 Aug 3.
10
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis.基因上调白介素 1 受体拮抗剂对代谢心血管的影响：一项孟德尔随机化分析。
Lancet Diabetes Endocrinol. 2015 Apr;3(4):243-53. doi: 10.1016/S2213-8587(15)00034-0. Epub 2015 Feb 26.